MAROSTICA, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 499
EU - Europa 349
AS - Asia 231
AF - Africa 1
Totale 1.080
Nazione #
US - Stati Uniti d'America 489
CN - Cina 230
IE - Irlanda 156
UA - Ucraina 61
FI - Finlandia 43
DE - Germania 27
SE - Svezia 20
GB - Regno Unito 15
IT - Italia 13
BE - Belgio 11
CA - Canada 6
MX - Messico 4
FR - Francia 1
GR - Grecia 1
HK - Hong Kong 1
MU - Mauritius 1
NL - Olanda 1
Totale 1.080
Città #
Dublin 156
Chandler 120
Jacksonville 86
Nanjing 62
Beijing 42
Ann Arbor 29
Ashburn 28
Wilmington 28
Nanchang 27
Jiaxing 20
Princeton 18
Dearborn 17
Hebei 17
Lawrence 16
Shenyang 16
Tianjin 16
Medford 13
Brussels 11
Boardman 10
Houston 10
Helsinki 8
Milan 8
Changsha 5
Hangzhou 5
Renton 5
Seattle 5
Shanghai 5
Toronto 5
Woodbridge 5
Morelia 4
Falls Church 3
Jinan 3
Kunming 3
Lanzhou 3
Ningbo 3
Norwalk 2
Pavia 2
Washington 2
Dolo 1
Groningen 1
Hefei 1
Newton 1
Redwood City 1
San Francisco 1
Surrey 1
Tappahannock 1
Vicenza 1
Xian 1
Totale 828
Nome #
First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis 88
Continuous-time Markov modelling of flexible-dose depression trials 78
Second order Markov modelling of HAMD responses in depression trials 70
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 69
A state-space approach to disease and dropout modelling in Phase II clinical trials 67
Population state-space modelling of patient responses in antidepressant studies 67
Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies 67
A PCA approach to population analysis: with application to a Phase II depression trial 63
Second-order indirect response modelling of complex biomarker dynamics 62
PCA-based modelling in antidepressant trials: a pre-mechanistic approach 57
Disease and dropout modelling in depression trials: a state-space approach 56
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 56
Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression 56
The GHRH+arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences 52
Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls 47
Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response 47
A new, second-order indirect model of depression time course 42
Population modelling of patient responses in antidepressant studies: A stochastic approach 41
Totale 1.085
Categoria #
all - tutte 3.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.126


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201937 0 0 0 0 0 0 0 0 17 6 7 7
2019/2020281 73 89 2 13 2 13 0 28 19 33 8 1
2020/2021125 17 12 5 14 0 15 2 17 3 20 16 4
2021/202279 3 1 5 3 3 3 2 5 8 1 10 35
2022/2023353 25 34 5 26 26 32 1 15 175 5 8 1
2023/202498 18 21 2 17 7 18 4 11 0 0 0 0
Totale 1.085